Serum beta 2 microglobulin in malignant lymphoproliferative disorders.

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Serum beta-2-microglobulin (S-beta 2M) is a protein found on the surface of lymphocytes.
• Elevated S-beta 2M levels have been associated with various hematologic malignancies.

Purpose of the Study:

• To investigate the diagnostic and prognostic significance of serum beta-2-microglobulin (S-beta 2M) in patients with lymphocytic leukemias and malignant lymphomas.
• To determine the correlation between S-beta 2M levels and clinical parameters, disease stage, and survival in these hematologic malignancies.

Main Methods:

• Serum beta-2-microglobulin (S-beta 2M) levels were measured at diagnosis in patients with chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD).
• Statistical analyses were performed to assess the association between S-beta 2M levels and clinical parameters such as tumor mass, lymphocyte counts, bone marrow infiltration, disease stage, splenomegaly, hepatomegaly, B symptoms, and patient survival.

Main Results:

• Elevated S-beta 2M levels were observed in 74% of CLL, 23.5% of ALL, 59.2% of NHL, and 40% of HD patients.
• In CLL, high S-beta 2M correlated with larger tumor mass, increased lymphocytes, and bone marrow infiltration, and was linked to poorer survival.
• In NHL and HD, S-beta 2M levels were associated with disease stage and splenomegaly. A significant relation with survival was found in HD patients with widespread disease.

Conclusions:

• Serum beta-2-microglobulin (S-beta 2M) is a valuable biomarker in lymphocytic leukemias and lymphomas, indicating disease burden and prognosis.
• S-beta 2M levels are particularly significant in chronic lymphocytic leukemia and Hodgkin's disease for predicting outcomes.
• Further research may explore the utility of S-beta 2M in guiding treatment strategies for these hematologic malignancies.